A detailed history of Creative Planning transactions in Cytosorbents Corp stock. As of the latest transaction made, Creative Planning holds 21,295 shares of CTSO stock, worth $20,656. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,295
Previous 21,295 -0.0%
Holding current value
$20,656
Previous $14,000 121.43%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 03, 2022

SELL
$1.2 - $2.46 $2,544 - $5,215
-2,120 Reduced 9.05%
21,295 $29,000
Q2 2022

Aug 15, 2022

BUY
$1.76 - $3.22 $3,731 - $6,826
2,120 Added 9.96%
23,415 $51,000
Q1 2022

May 16, 2022

SELL
$2.88 - $4.23 $2,880 - $4,230
-1,000 Reduced 4.49%
21,295 $68,000
Q4 2021

Feb 11, 2022

BUY
$4.05 - $8.11 $810 - $1,622
200 Added 0.91%
22,295 $93,000
Q3 2021

Nov 10, 2021

BUY
$7.0 - $9.71 $2,100 - $2,913
300 Added 1.38%
22,095 $179,000
Q2 2021

Aug 04, 2021

SELL
$7.55 - $9.42 $36,240 - $45,216
-4,800 Reduced 18.05%
21,795 $165,000
Q4 2020

Jan 29, 2021

BUY
$7.65 - $8.98 $1,530 - $1,796
200 Added 0.76%
26,595 $212,000
Q3 2020

Nov 05, 2020

SELL
$7.37 - $11.54 $61,465 - $96,243
-8,340 Reduced 24.01%
26,395 $211,000
Q2 2020

Jul 23, 2020

BUY
$6.28 - $10.59 $17,414 - $29,366
2,773 Added 8.68%
34,735 $344,000
Q1 2020

May 05, 2020

SELL
$3.77 - $7.73 $8,588 - $17,608
-2,278 Reduced 6.65%
31,962 $247,000
Q4 2019

Jan 30, 2020

SELL
$3.61 - $5.22 $541 - $783
-150 Reduced 0.44%
34,240 $132,000
Q1 2019

Apr 24, 2019

BUY
$6.82 - $8.56 $2,046 - $2,568
300 Added 0.88%
34,390 $260,000
Q3 2018

Oct 25, 2018

SELL
$10.95 - $14.8 $219,000 - $296,000
-20,000 Reduced 36.98%
34,090 $440,000
Q2 2018

Jul 20, 2018

BUY
$6.9 - $12.35 $373,221 - $668,011
54,090 New
54,090 $617,000

Others Institutions Holding CTSO

About Cytosorbents Corp


  • Ticker CTSO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 43,577,400
  • Market Cap $42.3M
  • Description
  • Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...
More about CTSO
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.